Successful Clinical Trials, Recognitions, Enrollment in Studies, Product Launches, and Strategic Announcements - Research Report

   Successful Clinical Trials, Recognitions, Enrollment in Studies, Product
Launches, and Strategic Announcements - Research Report on Boston Scientific,
                    Gilead, Abbott, Actavis, and Covidien

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 17, 2013

NEW YORK, September 17, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Boston
Scientific Corporation (NYSE: BSX), Gilead Sciences Inc. (NASDAQ: GILD),
Abbott Laboratories (NYSE: ABT), Actavis Inc. (NYSE: ACT), and Covidien plc
(NYSE: COV). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Boston Scientific Corporation Research Report 

On September 12, 2013, Boston Scientific Corporation (Boston Scientific)
announced that it has completed enrollment in the EVOLVE II randomized,
controlled clinical trial, a study designed to further assess the safety and
effectiveness of the SYNERGY Stent System and support US Food and Drug
Administration and Japanese regulatory approvals for the treatment of
atherosclerotic coronary lesions. Kevin Ballinger, President, Interventional
Cardiology, Boston Scientific, added, "Completing enrollment of EVOLVE II in
just nine months is just one example of how Boston Scientific and the
physician community are advancing cardiology together. The SYNERGY product
underscores our ongoing commitment to delivering meaningful innovation to the
interventional cardiology community and reinforces our position as a global
leader in medical devices." The Company informed that the 1,684 Patients
enrolled across 125 sites worldwide in the EVOLVE II trial will be followed
for five years. The Full Research Report on Boston Scientific Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-13/BSX]

Gilead Sciences Inc. Research Report

On September 12, 2013, Gilead Sciences Inc. (Gilead) announced results from a
Phase 2 study, evaluating an investigational once-daily tablet regimen
containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection.
Gilead informed that at 48 weeks, a regiment of elvitegravir 150 mg/cobicistat
150 mg/emtricitabine 200 mg/TAF 10 mg was found similar to Stribild
(elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir
disoproxil fumarate 300 mg) based on the percentage of patients with HIV RNA
levels less than 50 copies/mL, and was associated with more favorable renal
and bone safety markers. Commenting on the results, Norbert W. Bischofberger,
Phd, Gilead's Executive Vice President, Research and Development and Chief
Scientific Officer, said, "Based on these positive results, we believe that
TAF has the potential to become a key component of next-generation single
tablet regimens in HIV therapy. We are now completing enrollment of two Phase
3 clinical trials comparing a TAF-based regimen to Stribild in patients new to
HIV treatment, and look forward to sharing initial results from these
large-scale studies by the end of 2014." The Full Research Report on Gilead
Sciences Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-13/GILD]

Abbott Laboratories Research Report

On September 12, 2013, Abbott Laboratories (Abbott) announced that it has been
named as an Industry Group Leader in the 2013 Dow Jones Sustainability Index
(DJSI). According to the Company, this is the ninth consecutive year that
Abbott has made into the Dow Jones Sustainability World Index and North
America Index. The Company informed that it has been also selected as leader
in its specific DJSI industry sector, Health Care Equipment & Supplies, with
overall score of 82, which was significantly higher than the average score of
39 for other companies in the sector. The Company further added that it also
earned the highest scores across all three main areas of evaluation, including
economic, environmental, and social performance. Katherine Pickus, Divisional
Vice President, Global Citizenship and Policy at Abbott, said, "Abbott's
strong performance in the DJSI is a reflection of the company's longstanding
commitment to responsible and transparent business practices. Abbott strives
to foster economic, environmental and societal well-being through our
products, our core business operations and our partnerships with others." The
Full Research Report on Abbott Laboratories - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-09-13/ABT]

Actavis Inc. Research Report

On September 12, 2013, Actavis Inc. (Actavis) announced that it has launched
Oxymorphone Hydrochloride Extended-release tablets 5mg, 10mg, 30 mg, and 40
mg. The Company informed that Actavis' ANDA product is the generic equivalent
to the previously marketed formulation of Endo Health Solutions' (Endo) Opana
ER - an opioid agonist indicated for the relief of moderate to severe pain in
patients requiring continuous around-the-clock opioid treatment for an
extended period of time. Actavis stated that Opana ER was voluntarily
withdrawn from sale in 2012 by Endo. According to the Company, currently,
Actavis is a defendant in a lawsuit filed by Endo alleging that Actavis'
Oxymorphone Hydrochloride Extended-release product infringes certain of Endo's
patents. The Full Research Report on Actavis Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-09-13/ACT]

Covidien plc Research Report

On September 12, 2013, Covidien plc (Covidien) announced its key strategic
initiatives, growth opportunities, and innovations that are expected to drive
the Company's growth in 2014 and beyond at a meeting held for the investment
community. Covidien Chairman, President, and CEO Jose E. Almeida said,
"Despite the challenging external environment, we are delivering a very solid
performance in 2013. Our focus on growth, leverage and capital allocation will
be the drivers of our future performance. We will make further investments to
expand our capabilities, particularly in emerging markets, and to capitalize
on the market opportunities across our business." The Company further informed
that for full-year FY 2014, it anticipates net sales growth of 2% to 5% YoY.
The Full Research Report on Covidien plc - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investorsreports.com/report/2013-09-13/COV]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by an analyst. However, we are only human and are prone
    to make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

www.InvestorsReports.com

SOURCE Investors' Reports

Contact: Kristi Saunders, +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.